In a major scientific breakthrough that could redefine cancer treatment, Nigerian researcher Miss Temitope Ogunmola has made significant progress in decoding the complexities of the tumor microenvironment.
The work focuses on utilizing the Ubiquitin Proteasome System to target proteins that are overexpressed in cancer cells, marking a critical advancement in the development of precise and effective cancer therapies.
Ogunmola’s preclinical studies centered on renal cancer, a particularly deadly form of the disease that primarily affects older adults.
Her research highlights the role of senescent cells, commonly known as “zombie cells.”
These cells, though unable to divide, release inflammatory substances that fuel tumor growth and create a toxic environment for cancer to thrive.
By harnessing Proteolysis Targeting Chimeras (PROTACs), Ogunmola’s work introduces a new method of selectively eliminating these harmful cells. This innovative approach has the potential to revolutionize the treatment of renal cancer and other prevalent cancers, such as breast and prostate cancer.
Utilizing advanced techniques like single-cell RNA sequencing, Miss Ogunmola is exploring cancer at an unprecedented depth, aiming to translate her preclinical findings into lifesaving treatments. Her research offers hope not only for Nigeria, where cancer cases are on the rise, but for the global community.
With approximately 100,000 new cancer cases reported annually in Nigeria and limited access to advanced treatments, Miss Ogunmola’s work holds immense promise. Renal, breast, prostate, and cervical cancers are among the most common in the country, and her targeted therapies could offer a more effective, less invasive alternative to current treatments.
The potential global impact of her research is undeniable. With proper funding and collaboration with international biotech companies, Miss Ogunmola’s breakthrough could revolutionize cancer treatment worldwide, offering new hope in the fight against a disease that claims millions of lives each year.
and then